196 related articles for article (PubMed ID: 26667234)
1. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
[TBL] [Abstract][Full Text] [Related]
2. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
[TBL] [Abstract][Full Text] [Related]
3. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
4. Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.
Hagio K; Amano T; Hayashi H; Takeshita T; Oshino T; Kikuchi J; Ohhara Y; Yabe I; Kinoshita I; Nishihara H; Yamashita H
Sci Rep; 2021 Apr; 11(1):8109. PubMed ID: 33854152
[TBL] [Abstract][Full Text] [Related]
5. Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.
Page K; Guttery DS; Fernandez-Garcia D; Hills A; Hastings RK; Luo J; Goddard K; Shahin V; Woodley-Barker L; Rosales BM; Coombes RC; Stebbing J; Shaw JA
Clin Chem; 2017 Feb; 63(2):532-541. PubMed ID: 27940449
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
Maguire SL; Peck B; Wai PT; Campbell J; Barker H; Gulati A; Daley F; Vyse S; Huang P; Lord CJ; Farnie G; Brennan K; Natrajan R
J Pathol; 2016 Nov; 240(3):315-328. PubMed ID: 27512948
[TBL] [Abstract][Full Text] [Related]
7. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.
Frenel JS; Carreira S; Goodall J; Roda D; Perez-Lopez R; Tunariu N; Riisnaes R; Miranda S; Figueiredo I; Nava-Rodrigues D; Smith A; Leux C; Garcia-Murillas I; Ferraldeschi R; Lorente D; Mateo J; Ong M; Yap TA; Banerji U; Gasi Tandefelt D; Turner N; Attard G; de Bono JS
Clin Cancer Res; 2015 Oct; 21(20):4586-96. PubMed ID: 26085511
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
Guttery DS; Page K; Hills A; Woodley L; Marchese SD; Rghebi B; Hastings RK; Luo J; Pringle JH; Stebbing J; Coombes RC; Ali S; Shaw JA
Clin Chem; 2015 Jul; 61(7):974-82. PubMed ID: 25979954
[TBL] [Abstract][Full Text] [Related]
9. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.
Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Banks KC; Lanman RB; Talasaz A; Parker BA; Kurzrock R
Oncotarget; 2016 Mar; 7(9):9707-17. PubMed ID: 26848768
[TBL] [Abstract][Full Text] [Related]
10. Aneuploidy, TP53 mutation, and amplification of MYC correlate with increased intratumor heterogeneity and poor prognosis of breast cancer patients.
Oltmann J; Heselmeyer-Haddad K; Hernandez LS; Meyer R; Torres I; Hu Y; Doberstein N; Killian JK; Petersen D; Zhu YJ; Edelman DC; Meltzer PS; Schwartz R; Gertz EM; Schäffer AA; Auer G; Habermann JK; Ried T
Genes Chromosomes Cancer; 2018 Apr; 57(4):165-175. PubMed ID: 29181861
[TBL] [Abstract][Full Text] [Related]
11. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.
De Mattos-Arruda L; Weigelt B; Cortes J; Won HH; Ng CKY; Nuciforo P; Bidard FC; Aura C; Saura C; Peg V; Piscuoglio S; Oliveira M; Smolders Y; Patel P; Norton L; Tabernero J; Berger MF; Seoane J; Reis-Filho JS
Ann Oncol; 2014 Sep; 25(9):1729-1735. PubMed ID: 25009010
[TBL] [Abstract][Full Text] [Related]
12. Polarity gene alterations in pure invasive micropapillary carcinomas of the breast.
Gruel N; Benhamo V; Bhalshankar J; Popova T; Fréneaux P; Arnould L; Mariani O; Stern MH; Raynal V; Sastre-Garau X; Rouzier R; Delattre O; Vincent-Salomon A
Breast Cancer Res; 2014 May; 16(3):R46. PubMed ID: 24887297
[TBL] [Abstract][Full Text] [Related]
13. Detection of TP53 gene mutation in blood of breast cancer patients based on circulating tumor DNA and its application in prognosis.
Lu Q; Wei L; Cai S; Zhang Z; Zhang L
Cell Mol Biol (Noisy-le-grand); 2023 Nov; 69(11):200-206. PubMed ID: 38015519
[TBL] [Abstract][Full Text] [Related]
14. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.
Gonzalez-Angulo AM; Chen H; Karuturi MS; Chavez-MacGregor M; Tsavachidis S; Meric-Bernstam F; Do KA; Hortobagyi GN; Thompson PA; Mills GB; Bondy ML; Blumenschein GR
Cancer; 2013 Jan; 119(1):7-15. PubMed ID: 22736407
[TBL] [Abstract][Full Text] [Related]
15. Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
Keup C; Benyaa K; Hauch S; Sprenger-Haussels M; Tewes M; Mach P; Bittner AK; Kimmig R; Hahn P; Kasimir-Bauer S
Cell Mol Life Sci; 2020 Feb; 77(3):497-509. PubMed ID: 31254045
[TBL] [Abstract][Full Text] [Related]
16. Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.
Santarpia L; Bottai G; Kelly CM; Győrffy B; Székely B; Pusztai L
Oncologist; 2016 Sep; 21(9):1063-78. PubMed ID: 27384237
[TBL] [Abstract][Full Text] [Related]
17. Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53.
Ghaleb A; Yallowitz A; Marchenko N
Commun Biol; 2019; 2():436. PubMed ID: 31799437
[TBL] [Abstract][Full Text] [Related]
18. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy.
Shaw JA; Page K; Blighe K; Hava N; Guttery D; Ward B; Brown J; Ruangpratheep C; Stebbing J; Payne R; Palmieri C; Cleator S; Walker RA; Coombes RC
Genome Res; 2012 Feb; 22(2):220-31. PubMed ID: 21990379
[TBL] [Abstract][Full Text] [Related]
19. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
Janiszewska M; Liu L; Almendro V; Kuang Y; Paweletz C; Sakr RA; Weigelt B; Hanker AB; Chandarlapaty S; King TA; Reis-Filho JS; Arteaga CL; Park SY; Michor F; Polyak K
Nat Genet; 2015 Oct; 47(10):1212-9. PubMed ID: 26301495
[TBL] [Abstract][Full Text] [Related]
20. The targeted next-generation sequence revealed SMAD4, AKT1, and TP53 mutations from circulating cell-free DNA of breast cancer and its effect on protein structure - A computational approach.
Balasundaram A; Kumar S U; D TK; Anil Dedge A; R G; K SS; R S; C GPD
J Biomol Struct Dyn; 2023; 41(24):15584-15597. PubMed ID: 37011004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
